Company Filing History:
Years Active: 2025
Title: Innovations of Johannes Ottl in Metabolic Disorder Treatment
Introduction
Johannes Ottl is a notable inventor based in Lörrach, Germany. He has made significant contributions to the field of metabolic disorders through his innovative research and patenting activities. His work focuses on developing inhibitors that target specific proteins involved in lipid metabolism.
Latest Patents
Johannes Ottl holds a patent for "Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders." This patent relates to inhibitors of PCSK9, which are useful in treating lipid metabolism and other diseases where PCSK9 plays a crucial role. The patent outlines a specific formula that can be utilized in therapeutic applications.
Career Highlights
Ottl's career is marked by his association with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to collaborate with other experts in the field and contribute to groundbreaking research in metabolic disorders.
Collaborations
Throughout his career, Johannes has worked alongside notable colleagues such as Alec Nathanson Flyer and Andrei Alexandrovich Golosov. These collaborations have further enhanced his research and development efforts in the pharmaceutical industry.
Conclusion
Johannes Ottl's innovative work in developing PCSK9 inhibitors represents a significant advancement in the treatment of metabolic disorders. His contributions continue to impact the field positively, showcasing the importance of research and innovation in healthcare.